metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Influencia de la tiroidectomía sobre la pérdida de masa ósea en relación con...
Información de la revista
Vol. 69. Núm. 4.
Páginas 366-370 (abril 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 69. Núm. 4.
Páginas 366-370 (abril 2001)
Acceso a texto completo
Influencia de la tiroidectomía sobre la pérdida de masa ósea en relación con el déficit de calcitonina y el tratamiento con tiroxina
Influence of thyroidectomy and thyroxin treatment on bone mass loss and calcitonin deficit
Visitas
8753
H. Piñeiro Martínez*,1, P. Gil Gil**, N. Cáceres Alvarado***, C. Páramo Fernández****, C. Barbazán Álvarez*****, M.A. Andrade Olivié******, M.C. Gómez González*******, J. Potel Lesquereux********
* Jefe de Sección de Cirugía
** Jefe de Servicio de Cirugía
*** Médico adjunto de Cirugía
**** Médico adjunto de Endocrinología
***** Jefe de Sección de Reumatología
****** Médico adjunto. Laboratorio de Hormonas. Servicio de Análisis Clínicos.
******* Jefe de Sección de Bioquímica. Servicio de Cirugía General. Complejo Hospitalario Xeral-Cíes. Vigo.
******** Catedrático de Cirugía. Hospital Clínico Universitario. Santiago de Compostela.
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen
Introducción

Durante las últimas décadas se ha intentado valorar si la tiroidectomía y el tratamiento con tiroxina tienen un efecto negativo sobre la masa ósea. Los resultados publicados presentan discrepancias, faltan, además, estudios en pacientes con tratamiento sustitutivo.

Material y métodos

Se realiza un estudio de casos y controles, comparando a mujeres tiroidectomizadas (n = 60) con mujeres sin enfermedad tiroidea, de la misma situación estrogénica y edad, peso y talla similares. Se determinan T3, T4, TSH, PTH, vitamina D, calcitonina basal e inducida, densitometría ósea lumbar y femoral (AXD) y marcadores de la actividad ósea (osteocalcina, FATR, hidroxiprolina y deoxipiridinolina), así como las dosis de tiroxina y el tiempo de tratamiento en cada paciente.

Resultados

La comparación entre casos y controles no presentó diferencias en edad, peso, talla, PTH y vitamina D. No se hallaron diferencias densitométricas globales ni aumento de pérdida de densidad ósea en los subgrupos estrogénicos de las tiroidectomizadas. Tampoco se apreciaron diferencias en la osteocalcina y en la deoxipiridinolina. La calcitonina basal fue de 6,9 ± 4,4 pg/ml en los controles y de 4,6 ± 1,9 pg/ml en los casos (p < 0,01). No hubo respuesta al estímulo en las tiroidectomías totales, que presentó un incremento mínimo a los 5 minutos en las subtotales.

Conclusiones

No existe aumento de pérdida de mineral óseo en mujeres tiroidectomizadas por enfermedad benigna no hipertiroidea tratadas con tiroxina. Éstas presentan valores de calcitonina inferiores a los controles con incapacidad de respuesta al estímulo con calcio.

Palabras clave:
Tiroides
Masa ósea
Calcitonina
Introduction

During the last few decades attempts have been made to evaluate whether thyroidectomy and thyroxin treatment have a negative effect on bone mass. Published results are contradictory and studies of patients on replacement therapy are lacking.

Material and methods

A case control study was carried out. Women who had undergone thyroidectomy (n = 60) were compared with women with no thyroid abnormalities and with estrogen concentrations, age, weight and height similar to those of the thyroidectomized women. In each patient 3,5,3´-triiodothyronine, thyroxine, thyroid-stimulating hormone, parathyroid hormone, vitamin D, basal and induced calcitonin, lumbar and femoral bone densitometry (DXA) and bone activity markers (osteocalcin, FATR, hydroxyproline and deoxypyridinoline) as well as thyroxine doses and duration of treatment were determined.

Results

Comparison between patients and controls revealed no differences in age, weight, height, parathyroid hormone or vitamin D concentrations. No overall differences in bone density or increase in bone density loss were found in the subgroups of thyroidectomized divided according to estrogen concentrations. No differences were found in osteocalcin or deoxypyridinoline concentrations. Basal calcitonin was 6.9 ± 4.4 pg/ml in controls and 4.6 ± 1.9 in patients (p < 0.01). Patients with total thyroidectomy showed no response to stimulus while those with subtotal thyroidectomy showed a minimal increase at 5 minutes.

Conclusion

Patients with thyroidectomy for non-hyperthyroid benign disease undergoing thyroxine treatment showed no increase in bone mineral loss. These women showed lower concentrations of calcitonin than controls and were unable to respond to calcium stimulus.

Key words:
Thyroid
Bone mas
Calcitonin
El Texto completo está disponible en PDF
Bibliografía
[1.]
F.C. Von Recklinghausen.
Die Fibröse oder deformierende Ostitis, dieOsteomalazie und die osteoplastiche Carcinose in ihren gegenseitigen Beziehungen.
Festchrift Rudolf Virchof, pp. 347-352
[2.]
W.A. Plummer.
Cases showing osteoporosis due to decalcification in exopthalmic goiter.
Staff Meet Mayo Clin, 3 (1928), pp. 119-121
[3.]
P.J. Meunier, C.G.S. S-Bianchi, C.M. Eduard, J.C. Bernard, P. Courpron, G.E. Vignon.
Bone manifestations of thyrotoxicosis.
Orthop Clin North Am, 3 (1972), pp. 745-774
[4.]
B. Krolner, J.V. Jorgensen, S.P. Nielsen.
Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment.
Clin Endocrinol Oxf, 18 (1983), pp. 439-446
[5.]
M.T. McDermott, G.S. Kidd, P. Blue, V. Ghaed, F.D. Hofeldt.
Reduced bone mineral content in totally thyroidectomized patients: possible effect of calcitonin deficiency.
J Clin Edocrinol Metab, 56 (1983), pp. 936-939
[6.]
D.S. Ross.
Monitoring L-thyroxine therapy: lessons from the effects of L-thyroxine on bone density.
Am J Med, 91 (1994), pp. 1-4
[7.]
D.T. Baran.
Detrimental skeleton effects of thyrotropin suppresive dosses of thyroxine: Fact or fantasy?.
J Clin Endocrinol Metab, 78 (1994), pp. 816-817
[8.]
D.T. Baran.
Thyroid and bone mass: the clinician’s dilemma.
Thyroid, 4 (1994), pp. 143-144
[9.]
D.S. Ross, L.J. Ardison, M.J. Meskell.
Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminiscent assay.
J Clin Endocrinol Metab, 69 (1989), pp. 684-689
[10.]
D.S. Ross.
Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy.
Mayo Clinic Proc, 63 (1988), pp. 1223-1229
[11.]
A.H. Mudde, F.J.L. Reijnders, A.C. Nieuwenhuijzen Kruseman.
Peripheral bone density in women with untreated multinodular goitre.
Clin Endocrinol, 37 (1992), pp. 35-39
[12.]
J. Földes, G. Tarjan, M. Szathamari, F. Varga, I. Krasznai, C.S. Horvath.
Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporois?.
Clin Endocrinol, 39 (1993), pp. 521-527
[13.]
J.A. Kanis.
Patogénesis de la osteoporosis y fractura.
Osteoporosis,
[14.]
M.C. Monier-Faugere, M.C. Langub, H.H. Malluche.
Bone biopsies: a modern approach.
Metabolic bone disease and clinical related disorders,
[15.]
V. Adlin, A.H. Maurer, A. Marks, B.J. Channick.
Bone mineral density in postmenopausal women treated with L-thyroxine.
Am J Med, 90 (1991), pp. 360-366
[16.]
J. Lehmke, U. Bogner, D. Felsenberg, H. Peters, H. Schleusener.
Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
Clin Endocrinol, 36 (1992), pp. 511-517
[17.]
A.W.C. Kung, T. Lorentz, S.C.F. Tam.
Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Clin Endocrinol, 39 (1993), pp. 535-540
[18.]
J.A. Kanis, E.V. McCloskey, M.N.C. Beneton, J. Bernard, D. De Takats.
Bone measurements with DXA and ultrasound: diagnostic and prognostic use.
Osteoporosis 96,
[19.]
M. Uffmann, T.P. Fuerst, M. Jergas, H.K. Genant.
Noninvasive assesement of bone.
Metabolic bone disease and clinically related disorders,
[20.]
M.B. López, F. Hawkins, D. Rigopoulou, G. Martínez, E. Jodar, J. Estenoz, et al.
Factores de riesgo y densidad mineral ósea en mujeres en tratamiento prolongado con levotiroxina.
Med Clin (Barc, 112 (1999), pp. 85-89
[21.]
M.J. Välimäki, R. Tähtela, J.D. Jones, J.M. Peterson, B.L. Riggs.
Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxyl-terminal telepeptide of type I collagen and urinary pyridinium cross-links.
Eur J Endocrinol, 131 (1994), pp. 258-262
[22.]
P.D. Delmás.
Biochemical markers of bone remodeling in osteoporosis.
Osteoporosis 96,
[23.]
D.J. Grant, M.E.T. McMurdo, P.A. Mole, C.R. Paterson, R.R. Davies.
Supressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis.
Cli Endocrinol, 39 (1993), pp. 529-533
[24.]
J. Franklyn, J. Betteridge, R. Holder, J. Daykin, J. Lilley, M. Sheppard.
Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.
Clin Endocrinol, 41 (1994), pp. 425-432
[25.]
D.L. Hurley, R.D. Tiegs, H.W. Wahner, H. Heaths.
Axial and apendicular bone mineral density in patients with long-term deficiency or excess of calcitonin.
N Engl J Med, 317 (1987), pp. 537-541
[26.]
J.A. Franklyn, J. Betteridge, J. Daykin, R. Holder, G.D. Oates, J.V. Parle, et al.
Long-term thyroxine treatment and bone mineral density.
Lancet, 340 (1992), pp. 4-13
[27.]
K.W. Wenzel.
Bone minerals and levothyroxine.
Lancet, 240 (1992), pp. 435-436
[28.]
J. Lehmke, U. Bogner, D. Felsenberg, H. Peters, H. Schleusener.
Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
Clin Endocrinol, 36 (1992), pp. 511-517
[29.]
C. Marcocci, F. Golia, G. Bruno-Bossio, E. Vignali, A. Pinchera.
Carefully monitored levothyroxine supressive therapy is not associated with bone loss in premenopausal women.
J Clin Endocrinol Metab, 78 (1994), pp. 818-823
[30.]
F. Hawkins, D. Rigopoulou, K. Papapietro, M.B. López.
Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
Calcif Tissue, 54 (1994), pp. 16-19
[31.]
K. Fujiyama, T. Kiriyama, H. Kimura, K. Ashizawa, M. Tsura, Y. Nagayama, et al.
Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
Thyroid, 5 (1995), pp. 13-17
[32.]
G. Görres, A. Kalm, A. Otte, M. Götze, J. Müller-Brand.
Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
Eur J Nucl Med, 23 (1996), pp. 690-692
[33.]
T. Diamond, L. Nery, I. Hales.
A therapeutic dilemma: suppressive doses of thyroxine significantly reduced bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
J Clin Endocrinol, 72 (1991), pp. 1184-1188
[34.]
V. Adlin, A.H. Maurer, A. Marks, B.J. Channick.
Bone mineral density in postmenopausal women treated with L-thyroxine.
Am J Med, 90 (1991), pp. 360-366
[35.]
J.J. Stepán, Z. Límanová.
Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment.
Bone Miner, 17 (1992), pp. 377-388
[36.]
A.W.C. Kung, S.H.S.C. Yeung.
Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
J Clin Endocrinol Metab, 81 (1996), pp. 1232-1236
[37.]
J. Faber, A.M. Galloe.
Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.
Eur J Endocrinol, 130 (1994), pp. 350-356
[38.]
B. Uzzan, J. Campos, M. Cucherat, P. Nony, J.P. Boissel, G.Y. Perret.
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.
J Clin Endocrinol Metab, 81 (1996), pp. 4278-4289
[39.]
T.L. Paul, J. Kerrigan, A.M. Kelly, L.E. Braverman, D.T. Baran.
Longterm L-thyroxine therapy is associated with decreased hip bone density in premenopausal women.
JAMA, 259 (1988), pp. 3137-3141
[40.]
V.A. Livolsi.
Medullary carcinoma.
Surgical pathology of the thyroid,

Este trabajo ha sido realizado conuna ayuda de la Consellería de Educación e Ordenación Universitaria de Galicia (Xuga 90302A94).

Copyright © 2001. Asociación Española de Cirujanos
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos